Suzuki K, Takanashi K, Nagakubo I, Kiyosaki H, Naide Y
Department of Urology, Hiratsuka Municipal Hospital.
Jpn J Antibiot. 1987 Jul;40(7):1299-310.
Astromicin (ASTM) was administered by intravenous drip infusion (i.v.d.) to 22 patients with chronic complicated urinary tract infections and the clinical efficacy and safety of this drug were evaluated. The overall clinical efficacy rate obtained was 71.4% (excellent 6; moderate 9) of 21 evaluable cases by the UTI committee's criteria. Concerning the response on clinical isolates, the drug was highly effective especially against strains of Escherichia coli, indole positive Proteus and Serratia marcescens. It was not effective, however, against 2 strains of Pseudomonas aeruginosa. As for adverse reactions, there was one case which complained of headache on the 3rd day after starting treatment. In this case the drug administration was discontinued at the 5th day. The symptom disappeared within 24 hours without any treatment. No any other adverse reactions were noted. With regard to clinical test values for peripheral blood, liver and renal functions, no abnormality was observed in any of the cases treated with the drug. In conclusion, ASTM was found to be a highly effective and safe drug when administered by intravenous drip infusion in the treatment of chronic complicated urinary tract infections.
对22例慢性复杂性尿路感染患者静脉滴注阿司米星（ASTM），并评估该药的临床疗效和安全性。根据泌尿道感染委员会的标准，在21例可评估病例中，总体临床有效率为71.4%（优6例；中9例）。关于对临床分离株的反应，该药对大肠杆菌、吲哚阳性变形杆菌和粘质沙雷氏菌菌株特别有效。然而，对2株铜绿假单胞菌无效。至于不良反应，有1例在开始治疗后第3天抱怨头痛。该病例在第5天停药。未经任何治疗，症状在24小时内消失。未观察到任何其他不良反应。关于外周血、肝肾功能的临床检测值，在接受该药治疗的任何病例中均未观察到异常。总之，发现ASTM静脉滴注给药治疗慢性复杂性尿路感染时是一种高效且安全的药物。
